Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

Daré plans compounded sildenafil cream rollout in 28 states; no sales figures yet

The women's health company's third-quarter update puts a compounding-based launch ahead of its pipeline readouts, but no revenue data accompanied the announcement.

16 Nov 2026 · Dare Bioscience, Inc. DARE · Company news

Daré Bioscience is preparing to put its sildenafil cream into patients' hands before the end of November, with dispensing expected in 28 states. The company gave the timing on 16 November 2026 as it reported results for the quarter ended 30 September. It is using the Section 503B outsourcing-facility route rather than an approved-drug launch, and the information provided contains no revenue, pricing or volume data for the product.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Dare Bioscience, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →